4月24日 - ** Galderma GALD.S股价上涨 5.7%，该公司公布的第一季度财报 (link) 超过预期，主要原因是其注射美容部门的销售额增加。
** 注射美容部门的销售额同比增长9.9%，Jefferies和J.P. Morgan的分析师指出，这比共识高出6%，主要是受到神经调节剂销售额的推动。
** 美国销售额未达到一致预期，但国际销售额 "令人愉悦的两位数 "增长抵消了这一影响。
** 分析师称，特应性皮炎和结节性瘙痒症药物Nemluvio在美国的销售情况好于预期，Jefferies认为 "与赛诺菲SASY.PA/RegeneronREGN.O的Dupixent和礼来LLY.N的Ebglyss相比，该药物的销售轨迹很有希望"。
** 截至上一交易日收盘，股价累计下跌 19.9
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.